Skip to main content
OpenTrials
Completed

NCT Number: NCT01973218

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

The purpose of the study was to assess the immunogenicity and safety of two doses of Novartis Meningococcal B Recombinant (rMenB+OMV NZ) vaccine administered one month apart (0, 1 month schedule) in Korean adolescents aged between 11 to 17 years.

Completed

Looking for future studies?

Notify Me

Key information

Age range

11 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

06 Kosin University Gospel Hospital 34, amnam-dong, Seo-gu, Busan, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adolescents 11-17 years of age inclusive who have given their written assent and whose parent or legal guardian has given written informed consent at the time of enrollment;
  • Available for all the visits scheduled in the study (i.e. not planning to leave the area before the end of the study period);
  • In good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator;
  • With a negative urine pregnancy test (for female subjects only).

Exclusion criteria

  • History of any meningococcal vaccine administration;
  • Current or previous, confirmed or suspected disease caused by N. meningitidis;
  • Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;
  • Pregnancy or nursing (breastfeeding) mothers;
  • Female subjects who have not used or do not plan to use acceptable birth control measures, for the 2 months duration of the study;
  • Any serious chronic or progressive disease;
  • Family members and household members of research staff;
  • Any condition which in the opinion of the investigator may interfere with the evaluation of the study objectives;
  • Significant acute or chronic infection within the previous 7 days or fever within 3 days prior to enrolment;
  • Antibiotics within 6 days prior to enrollment;
  • Known or suspected impairment/alteration of the immune system, immunosuppressive therapy;
  • Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;
  • History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component;
  • Receipt of or intent to immunize with any other vaccine(s) within 30 days prior and throughout the study period;
  • Participation in another clinical trial within the last 90 days or planned for during study.

Treatment and study plan

Meningococcal B Recombinant vaccine rMenB+OMV NZ

Biological

Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.

Placebo

Biological

Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.

Meningococcal ACWY-CRM conjugate vaccine

Biological

Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.

Other names: Meningococcal (groups A,C,W,and Y) oligosaccharide diphtheria CRM-197

Primary outcomes

  1. Percentage of Subjects With Serum Bactericidal Antibody (SBA) Titers ≥1:4 Against Neisseria Meningitidis Serogroup B by Vaccine Group.

    Time frame: Day 1 and Day 61

    Percentage of subjects with SBA titers ≥1:4 against each of the three indicators strains H44/76, 5/99 and NZ98/254 of N. Meningitidis serogroup B, at one month after second vaccination, are reported for each group.

Secondary outcomes

  1. The SBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B, by Vaccine Group.

    Time frame: Day 1 and Day 61

    The SBA antibody titers against each of the three indicator strains of N.Meningitidis serogroup B at one month after second vaccination are reported as GMTs, for each group.

  2. The Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination SBA Titers Against N.Meningitidis Serogroup B, by Vaccine Group.

    Time frame: Day 61/ Day 1

    The GMR of post-vaccination versus pre-vaccination SBA titers against each of the three indicator strains of N.Meningitidis serogroup B, at one month after second vaccination (day 61/day 1) are reported, for each group.

  3. The Percentages of Subjects With a Four-fold Increase in SBA Antibody Titers Against N.Meningitidis Serogroup B, by Vaccine Group.

    Time frame: Day 61

    Percentages of subjects with a four-fold increase in SBA antibody titers from baseline against each of the three indicator strains of N.Meningitidis serogroup B, at one month after second vaccination are reported, for each group.

  4. The ELISA Geometric Mean Concentrations (GMCs) Against Vaccine Antigen 287-953, by Vaccine Group.

    Time frame: Day 1 and Day 61

    The GMCs against vaccine antigen 287-953 was measured by Enzyme-linked Immunosorbent Assay (ELISA) , at one month after second vaccination and are reported for each group.

  5. The GMR of Post Versus Pre-vaccination ELISA GMCs Against Vaccine Antigen 287-953, by Vaccine Groups.

    Time frame: Day 61/Day 1

    The GMR of post versus pre-vaccination GMCs against vaccine antigen 287-953, measured by ELISA at one month after second vaccination (day 61/day 1) are reported for each group.

  6. The Number of Subjects Reporting Solicited Adverse Events After Each Study Vaccination, by Vaccine Group.

    Time frame: Day 1 through day 7 after each vaccination

    The number of subjects reporting solicited local and systemic adverse events (AEs) following rMenB+OMV NZ vaccination or placebo/MenACWY-CRM, are reported.

  7. The Number of Subjects Reporting Unsolicited AEs After Any Vaccination, by Vaccine Group.

    Time frame: Day 1 through Day 61

    The number of subjects reporting any unsolicited AEs, serious adverse events (SAEs), AEs leading to premature withdrawal and medically attended AEs (throughout the study), following rMenB+OMV NZ vaccination or placebo/MenACWY-CRM, are reported.

Sponsors and collaborators

Lead sponsor

Novartis Vaccines

Industry

Collaborators

  • Novartis

Registry information

Official study title

A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Oct 31, 2013
Registry last updated
Oct 30, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.